Optimizing nucleotide modifications in the binding arms and catalytic core of '10-23' DNAzymes significantly enhances their RNA cleavage activity and nuclease stability.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use; leaves open therapeutic testing of optimized DNAzymes in cardiovascular models.
Steffen Schubert (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: